Thomas J Kelly Jr., PhD

Research Program: Cancer Biology Faculty Rank: Professor Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: Pathology Research Faculty

Cancer Research Interest

• Disease Site Focus: Breast
• Research Focus Area: Health Disparities, Treatment, Carcinogenesis, Diagnosis/ Prognosis
• Type of Research: Basic
• Research Interest Statement: I study the tumor microenvironment and the role of normal host cells such as fibroblasts and macrophages in promoting outgrowth and metastasis of tumors. I am focused primarily on breast cancer and use both the Mouse Mammary Tumor Virus-Polyma Middle T model as well as clinical samples.

Contact Information

• Email Address: KELLYTHOMASJ@UAMS.EDU
• Profiles Research Networking Software: View Profile

Active Grants

• State of Arkansas – AWD00056273
  “In Vivo Evaluation of Monensin, its Analogs, and Immune Checkpoint Inhibitors in Breast Cancer: Efficacy and Toxicity Analysis”
  Co-Investigator
  9/1/2024 – 8/31/2026
• NIH/Nat. Cancer Institute – 1R21CA280448
  “SR-A as a therapeutic target in breast cancer”
  Co-Investigator
  1/1/2024 – 12/31/2025

Recent Publications

• Tesfay MZ, Zhang Y, Ferdous KU, [et al., including Kelly T]. Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade. Molecular therapy. Oncology. 2024 32(4):200913. PMID: 39758249. PMCID: PMC11697550.
• Ferdous KU, Tesfay MZ, Cios A, [et al., including Kelly T]. Enhancing Neoadjuvant Virotherapy's Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer. Biomedicines. 2024 12(7). PMID: 39062169. PMCID: PMC11275208.
• Boyanton BL Jr, Zarate YA, Broadfoot BG, [et al., including Kelly T]. NR3C2 microdeletions-an underrecognized cause of pseudohypoaldosteronism type 1A: a case report and literature review. Laboratory medicine. 2024. PMID: 38493321.
• Monzavi-Karbassi B, Kelly T, Post SR. The Tumor Microenvironment and Immune Response in Breast Cancer. International journal of molecular sciences. 2024 25(2). PMID: 38255987. PMCID: PMC10815817.
• Chen J, Lin Z, Fan J, [et al., including Kelly T]. Identification of new microtubule small-molecule inhibitors and microtubule-associated genes against triple negative breast cancer. American journal of cancer research. 2024 14(4):1545-1560. PMID: 38726264. PMCID: PMC11076258.
• Marin LP, Presley JH, Noori K, [et al., including Kelly T]. Partnership in Cancer Research (PCAR) Program Increases Medical Student Knowledge and Confidence to Perform Cancer Research. Journal of cancer education : the official journal of the American Association for Cancer Education. 2023. PMID: 37957501. PMCID: PMC10995089.
• Nounamo B, Jousheghany F, Siegel ER, [et al., including Kelly T]. VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen. International journal of molecular sciences. 2023 24(3). PMID: 36768830. PMCID: PMC9917008.
• Zhang Y, Gabere M, Taylor MA, [et al., including Kelly T]. Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy. Frontiers in oncology. 2022 12:1042250. PMID: 36457491. PMCID: PMC9706410.